scPharmaceuticals Inc
SCPH5.500USD
+0.330+6.38%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
276.56MCap. mercado
PérdidaP/E TTM
Más Datos de scPharmaceuticals Inc Compañía
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Información de la empresa
Símbolo de cotizaciónSCPH
Nombre de la empresascPharmaceuticals Inc
Fecha de salida a bolsaNov 17, 2017
Director ejecutivoMr. John H. Tucker
Número de empleados162
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección25 Burlington Mall Road, Suite 203
CiudadBURLINGTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal01803
Teléfono16175170730
Sitio Webhttps://www.scpharmaceuticals.com/
Símbolo de cotizaciónSCPH
Fecha de salida a bolsaNov 17, 2017
Director ejecutivoMr. John H. Tucker
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Klaus Veitinger, M.D., Ph.D.
Dr. Klaus Veitinger, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William T. Abraham, M.D.
Dr. William T. Abraham, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
26.77%
Private Equity
17.92%
Hedge Fund
15.19%
Investment Advisor/Hedge Fund
11.23%
Individual Investor
6.08%
Research Firm
3.79%
Venture Capital
2.27%
Bank and Trust
0.15%
Pension Fund
0.03%
Other
16.57%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
207
44.05M
83.43%
-9.61M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
2023Q1
135
26.76M
76.80%
-865.96K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
OrbiMed Advisors, LLC
6.06M
11.48%
--
--
Mar 31, 2025
Rubric Capital Management LP
4.78M
9.04%
--
--
Mar 31, 2025
Luther King Capital Management Corp.
3.12M
5.91%
+263.26K
+9.21%
Mar 31, 2025
Lytton (Laurence W)
2.94M
5.58%
+1.12M
+61.35%
Sep 30, 2024
AIGH Capital Management, LLC.
3.10M
5.86%
--
--
Mar 31, 2025
Lundbeckfond Invest
2.86M
5.42%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.15M
4.08%
+43.64K
+2.07%
Mar 31, 2025
The Vanguard Group, Inc.
1.99M
3.77%
-115.70K
-5.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.65M
3.12%
-29.52K
-1.76%
Mar 31, 2025
Rice Hall James & Associates, LLC
1.40M
2.65%
+408.42K
+41.27%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 3000 ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.47%
iShares Micro-Cap ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 3000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
